Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
Luke JJ, Long GV, Robert C, Carlino MS, Choueiri TK, Haas NB, O'Brien M, Paz-Ares L, Peters S, Powles T, Leiby MA, Lin J, Zhao Y, Krepler C, Perini RF, Catherine Pietanza M, Samkari A, Gruber T, Ibrahim N, Eggermont AMM.
Luke JJ, et al. Among authors: ibrahim n.
Eur J Cancer. 2024 May 31;207:114146. doi: 10.1016/j.ejca.2024.114146. Online ahead of print.
Eur J Cancer. 2024.
PMID: 38838446